Evidence map›Paper›PMID 35757604›Full record

ArticleFrontiers in public health2022

The Impact of Pre-analytical Quality Initiatives on Cholangiocarcinoma Diagnostics in Thailand.

Supinda Koonmee, Sakkarn Sangkhamanon, Piyapharom Intarawichian, Chaiwat Aphivatanasiri, Waritta Kunprom, Prakasit Sa-Ngiamwibool, Suwit Balthaisong, Chitsakul Phuyao, Piya Prajumwongs, Reza Alaghehbandan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Supinda KoonmeeCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Sakkarn SangkhamanonCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Piyapharom IntarawichianCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Chaiwat AphivatanasiriCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Waritta KunpromCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Prakasit Sa-NgiamwiboolCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Suwit BalthaisongCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Chitsakul PhuyaoCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Piya PrajumwongsCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Reza AlaghehbandanDepartment of Pathology, Faculty of Medicine, Royal Columbian Hospital, University of British Columbia, Vancouver, BC, Canada.
Malinee ThaneeCholangiocarcinoma Screening and Care Program, Khon Kaen University, Khon Kaen, Thailand.
Khon Kaen University · THRoyal Columbian Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is the most prevalent malignancy in Thailand, with unfortunate late diagnosis and frequent metastatic disease outcomes. An accurate tissue diagnosis is the first and most important step in the treatment of CCA. Tissue quality and preservation during the pre-analytical phase play major roles in the proper histological evaluation and potential biomarker testing. This study evaluated the impact of using the "Cholangiocarcinoma Screening and Care Program (CASCAP)" container, as an innovative tool to address pre-analytical challenges faced by pathology laboratories in Thailand. This is a comparison study examining the quality of CCA specimens using the CASCAP container vs. the conventional method, using hematoxylin and eosin (H&E) and immunohistochemistry (IHC). CCA tissue quality using the CASCAP container significantly reduced artifact deposition while improving the cellular structure and nuclear and cytoplasmic morphologies. The immunohistochemical expression of cytokeratin 19 (CK19), a prognostic marker in CCA, significantly improved in the CASCAP container group in comparison with the conventional method. This innovation is proven to significantly enhance the CCA tissue quality diagnostics and prognostic biomarker testing, hence improving overall cancer care, diagnosis, and treatment in Thailand.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaBile Ducts, IntrahepaticHumansMass ScreeningThailandcholangiocarcinomahistopathologyimmunohistochemistrypre-analytical phasetissue preservation

Identifiers

PMID35757604
PMCPMC9231639
OpenAlexW4281929066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.